This point is particularly poignant considering withdrawals of certain RIPK1 inhibitor drugs from phase I (pancreatic cancer) and II (chronic inflammatory diseases) clinical trials due to lack of efficacy [98,99]. The gene discussed is RIPK1; the disease is familial pancreatic carcinoma.